Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia

被引：14

作者：

Arora, B ^{[1
]}

Mesa, RA ^{[1
]}

Tefferi, A ^{[1
]}

机构：

[1] Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA

来源：

LEUKEMIA & LYMPHOMA | 2004年 / 45卷 / 12期

关键词：

myleofibrosis; agnogenic myeloid metaplasia; angiogenesis; anti-antigenesis treatment; myelofibrosis therapy; MPD;

D O I：

10.1080/10428190400003267

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.

引用

页码：2373 / 2386

页数：14

共 185 条

[1]

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2]

Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].

Aguayo, A ;

Estey, E ;

Kantarjian, H ;

Mansouri, T ;

Gidel, C ;

Keating, M ;

Giles, F ;

Estrov, Z ;

Barlogie, B ;

Albitar, M .

BLOOD, 1999, 94 (11) :3717-3721

[3]

Reactive oxygen generated by Nox1 triggers the angiogenic switch [J].

Arbiser, JL ;

Petros, J ;

Klafter, R ;

Govindajaran, B ;

McLaughlin, ER ;

Brown, LF ;

Cohen, C ;

Moses, M ;

Kilroy, S ;

Arnold, RS ;

Lambeth, JD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) :715-720

[4]

SYNERGISTIC EFFECT OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND BASIC FIBROBLAST GROWTH-FACTOR ON ANGIOGENESIS IN-VIVO [J].

ASAHARA, T ;

BAUTERS, C ;

ZHENG, LP ;

TAKESHITA, S ;

BUNTING, S ;

FERRARA, N ;

SYMES, JF ;

ISNER, JM .

CIRCULATION, 1995, 92 (09) :365-371

[5]

Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors [J].

Avet-Loiseau, H ;

Gerson, F ;

Magrangeas, F ;

Minvielle, S ;

Harousseau, JL ;

Bataille, R .

BLOOD, 2001, 98 (10) :3082-3086

[6]

Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors [J].

Barleon B. ;

Reusch P. ;

Totzke F. ;

Herzog C. ;

Keck C. ;

Martiny-Baron G. ;

Marmé D. .

Angiogenesis, 2001, 4 (2) :143-154

[7]

Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia [J].

Barosi, G ;

Vittorio, R ;

Margherita, MS ;

Luca, VG ;

Alessandro, P ;

Vittorio, N ;

Isabella, R ;

Rita, C ;

Monia, M ;

Mario, B ;

Is, MNAEH .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (05) :618-625

[8]

A PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA [J].

BAROSI, G ;

BERZUINI, C ;

LIBERATO, LN ;

COSTA, A ;

POLINO, G ;

ASCARI, E .

BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (04) :397-401

[9]

Barosi G, 2002, BLOOD, V100, p800A

[10]

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia [J].

Barosi, G ;

Grossi, A ;

Comotti, B ;

Musto, P ;

Gamba, G ;

Marchetti, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (01) :78-83

← 1 2 3 4 5 6 7 8 9 10 →